According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), which of the following conditions is classified as UKMEC category 4 (unacceptable health risk) for the combined oral contraceptive pill?
Q132
A 53-year-old woman who underwent bilateral salpingo-oophorectomy at age 48 for endometriosis has been taking oestrogen-only HRT since surgery. She now presents requesting to stop HRT as she believes she has 'gone through the menopause naturally'. Her current symptoms are well-controlled on transdermal oestradiol 50 mcg patches. What is the most appropriate advice regarding HRT continuation?
Q133
A 41-year-old woman with a BMI of 38 kg/m² attends for insertion of a levonorgestrel intrauterine system for contraception and management of heavy menstrual bleeding. The procedure is technically difficult and after multiple attempts, you are unable to sound the uterus beyond 4 cm or pass the IUS through the internal os. The patient tolerates the procedure but finds it uncomfortable. What is the most appropriate next step in management?
Q134
A 50-year-old woman presents with vaginal dryness and dyspareunia 18 months after her last menstrual period. She has no systemic menopausal symptoms. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 3 years ago. She is currently taking tamoxifen. What is the most appropriate initial management for her genitourinary symptoms?
Q135
A 27-year-old woman presents requesting contraception. She mentions that she sometimes forgets to take daily medication. She has no significant medical history and takes no regular medications. Her BMI is 32 kg/m² and blood pressure is 118/76 mmHg. She is in a stable relationship and would like to have children in approximately 3 years. Which contraceptive method would be most appropriate to recommend?
Q136
A 34-year-old woman attends for contraceptive counselling. She smokes 15 cigarettes per day and has a blood pressure of 158/98 mmHg on two separate occasions. Her BMI is 28 kg/m². She has no other medical history. Blood tests including renal function and lipid profile are normal. What is the most appropriate contraceptive method for this patient?
Q137
A 43-year-old woman attends for contraceptive advice. She is currently using condoms. She smokes 25 cigarettes per day and has a BMI of 33 kg/m². Her blood pressure is 142/90 mmHg on two separate occasions. She has regular menstrual cycles and wishes to continue menstruating. She has no other medical history. After counseling about smoking cessation and lifestyle modification, which contraceptive method would be most appropriate while addressing her cardiovascular risk profile?
Q138
A 57-year-old woman with type 2 diabetes mellitus presents requesting HRT for moderate vasomotor symptoms that are affecting her sleep. Her last menstrual period was 3 years ago. Her HbA1c is 58 mmol/mol (7.5%), BMI is 29 kg/m², and blood pressure is 136/84 mmHg. She has background diabetic retinopathy but no other diabetic complications. She takes metformin and gliclazide. What factor would represent the greatest relative contraindication to HRT in this patient?
Q139
A 33-year-old woman with a 6-month history of migraine with aura has been using combined oral contraceptive pills for 4 years. She presents for a routine contraceptive review. Her migraines have increased in frequency from once every 3 months to 2-3 times per month over the past 6 months. She has no other medical history and her blood pressure is 122/78 mmHg. What is the most appropriate management of her contraception?
Q140
A 56-year-old woman who has been on continuous combined HRT for 3 years presents for review. She remains asymptomatic with good control of vasomotor symptoms. She asks about when she should stop HRT. She has no history of premature ovarian insufficiency, cardiovascular disease, or osteoporosis risk factors. What is the most appropriate advice regarding continuation of HRT?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 131: According to the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC), which of the following conditions is classified as UKMEC category 4 (unacceptable health risk) for the combined oral contraceptive pill?
A. History of venous thromboembolism while pregnant
B. Migraine without aura in a 38-year-old woman
C. Current breast cancer (Correct Answer)
D. Controlled hypertension with blood pressure 138/88 mmHg
E. Breastfeeding between 6 weeks and 6 months postpartum
Explanation: ***Current breast cancer***
- **Current breast cancer** is classified as **UKMEC 4** (unacceptable health risk) because it is a **hormone-sensitive malignancy** that can be promoted by exogenous oestrogen from the **combined oral contraceptive pill (COCP)**.
- Using COCP in this situation significantly increases the risk of **disease progression** or recurrence, making it an absolute contraindication.
*History of venous thromboembolism while pregnant*
- A **personal history of VTE** that was associated with a **transient risk factor** (like pregnancy or surgery) is classified as **UKMEC 3** for the COCP.
- This means the risks generally outweigh the benefits, but it is not an absolute contraindication (UKMEC 4).
*Migraine without aura in a 38-year-old woman*
- **Migraine without aura** at any age is classified as **UKMEC 2** for the COCP, meaning the advantages generally outweigh the risks.
- It is **migraine with aura** that is classified as **UKMEC 4** due to the significantly increased risk of **ischaemic stroke** with oestrogen-containing contraceptives.
*Controlled hypertension with blood pressure 138/88 mmHg*
- **Controlled hypertension** with a blood pressure reading between **140-159/90-99 mmHg** (and therefore 138/88 mmHg) is classified as **UKMEC 3** for the COCP.
- Hypertension is only classified as **UKMEC 4** if the blood pressure is **≥160/100 mmHg** or if there is associated **vascular disease**.
*Breastfeeding between 6 weeks and 6 months postpartum*
- **Breastfeeding** during the period of **6 weeks to 6 months postpartum** is classified as **UKMEC 3** for the COCP.
- This is due to theoretical concerns regarding the impact of oestrogen on **milk volume** and potential effects on infant growth, but it is not an absolute contraindication.
Question 132: A 53-year-old woman who underwent bilateral salpingo-oophorectomy at age 48 for endometriosis has been taking oestrogen-only HRT since surgery. She now presents requesting to stop HRT as she believes she has 'gone through the menopause naturally'. Her current symptoms are well-controlled on transdermal oestradiol 50 mcg patches. What is the most appropriate advice regarding HRT continuation?
A. She can stop HRT immediately as she is now past the average age of menopause
B. She should continue HRT until at least age 55 to cover the physiological age of menopause (Correct Answer)
C. She should have FSH levels checked to determine if she can stop HRT
D. She should reduce to the lowest dose and stop within the next year
E. She should continue HRT until age 51, which is the average age of natural menopause
Explanation: ***She should continue HRT until at least age 55 to cover the physiological age of menopause***
- For women who experience **iatrogenic menopause** (surgical removal of ovaries) before the natural age, it is recommended to continue HRT until at least **age 55**.
- This continuation mitigates long-term health risks such as **osteoporosis**, **cardiovascular disease**, and **cognitive decline** associated with prolonged oestrogen deficiency after early surgical menopause.
*She can stop HRT immediately as she is now past the average age of menopause*
- While 51 is the average age, the physiological age range for natural menopause extends up to **age 55 and beyond**.
- Stopping abruptly at 53, especially after surgical menopause, can lead to a resurgence of **vasomotor symptoms** and a loss of protective benefits.
*She should have FSH levels checked to determine if she can stop HRT*
- **FSH levels** are not a reliable indicator in women who are currently on HRT, as exogenous oestrogen suppresses the **pituitary gland's production** of gonadotropins.
- Clinical decisions regarding HRT continuation should be based on **age**, symptoms, and individual risk factors, rather than biochemical markers while on treatment.
*She should reduce to the lowest dose and stop within the next year*
- While gradual tapering can be considered, stopping HRT by age 54 (within the next year) would still be **premature** relative to the recommended continuation until at least 55 for those with iatrogenic menopause.
- A transdermal oestradiol 50 mcg patch is a standard dose, and reducing it further or stopping early could compromise **bone mineral density** and cardiovascular protection.
*She should continue HRT until age 51, which is the average age of natural menopause*
- Continuing only until age 51, the average age of menopause, does not adequately cover the **natural physiological range** which extends to at least 55.
- The aim for women with early surgical menopause is to replace oestrogen for the full duration their ovaries would have naturally produced it, typically until **age 55**.
Question 133: A 41-year-old woman with a BMI of 38 kg/m² attends for insertion of a levonorgestrel intrauterine system for contraception and management of heavy menstrual bleeding. The procedure is technically difficult and after multiple attempts, you are unable to sound the uterus beyond 4 cm or pass the IUS through the internal os. The patient tolerates the procedure but finds it uncomfortable. What is the most appropriate next step in management?
A. Attempt insertion again after administering misoprostol to soften the cervix
B. Refer for insertion under ultrasound guidance
C. Prescribe tranexamic acid and arrange hysteroscopy to assess uterine cavity
D. Arrange pelvic ultrasound and consider alternative contraceptive methods (Correct Answer)
E. Book for insertion under general anaesthesia
Explanation: ***Arrange pelvic ultrasound and consider alternative contraceptive methods***- When the uterus cannot be sounded beyond **4 cm** (normal is 6-9 cm), it is essential to perform a **pelvic ultrasound** to exclude anatomical abnormalities like **fibroids**, **uterine anomalies**, or **cervical stenosis**.- While awaiting investigation, discussing **alternative contraception** (e.g., implant or depot) is crucial to prevent pregnancy and manage her **heavy menstrual bleeding**.*Attempt insertion again after administering misoprostol to soften the cervix*- **Misoprostol** for cervical priming is generally not recommended for routine use and should not be used after a failed attempt without first identifying the **underlying anatomical cause** of the difficulty.- Re-attempting blindly increases the risk of **uterine perforation** or significant patient distress if the cause is not simple cervical resistance.*Refer for insertion under ultrasound guidance*- **Ultrasound-guided insertion** is a valid technique but is typically utilized only after a diagnostic ultrasound has confirmed the uterine anatomy is suitable for an **IUS**.- It is premature to refer for this procedure until structural issues like a **submucous fibroid** or **congenital anomaly** have been assessed.*Prescribe tranexamic acid and arrange hysteroscopy to assess uterine cavity*- While **tranexamic acid** manages bleeding, **hysteroscopy** is an invasive second-line investigation that should only follow a **non-invasive pelvic ultrasound**.- This approach neglects the immediate need for **effective contraception**, which is the patient's primary reason for the visit.*Book for insertion under general anaesthesia*- **General anaesthesia** may overcome patient discomfort but does not address the potential anatomical barrier that prevented sounding beyond **4 cm**.- Moving directly to surgery carries unnecessary **anaesthetic risks**, especially in a patient with a high **BMI of 38 kg/m²**, before basic imaging is performed.
Question 134: A 50-year-old woman presents with vaginal dryness and dyspareunia 18 months after her last menstrual period. She has no systemic menopausal symptoms. She has a history of oestrogen receptor-positive breast cancer treated with wide local excision and radiotherapy 3 years ago. She is currently taking tamoxifen. What is the most appropriate initial management for her genitourinary symptoms?
A. Systemic continuous combined HRT
B. Vaginal oestrogen therapy
C. Vaginal lubricants and moisturisers (Correct Answer)
D. Tibolone
E. Topical testosterone cream
Explanation: ***Vaginal lubricants and moisturisers***
- These are the **first-line therapy** for managing **genitourinary syndrome of menopause (GSM)** in patients with a history of **oestrogen receptor-positive breast cancer**.
- They provide symptomatic relief without **systemic absorption**, avoiding the risk of stimulating residual breast cancer cells or interfering with **tamoxifen** therapy.
*Systemic continuous combined HRT*
- This is **contraindicated** in women with a history of **hormone-sensitive breast cancer** as it significantly increases the risk of recurrence.
- The patient also lacks **vasomotor symptoms** (e.g., hot flushes), making systemic therapy unnecessary and inappropriate.
*Vaginal oestrogen therapy*
- While effective for **atrophic vaginitis**, it is reserved as a second-line option in breast cancer survivors only if **non-hormonal treatments** fail.
- There is a theoretical concern regarding **systemic absorption** of oestrogen, which requires a multidisciplinary discussion with an **oncologist** before initiation.
*Tibolone*
- Tibolone is a synthetic steroid with **oestrogenic, progestogenic, and androgenic** properties, which is contraindicated in survivors of breast cancer.
- Evidence suggests it is associated with an increased risk of **breast cancer recurrence**.
*Topical testosterone cream*
- This is primarily used for **hypoactive sexual desire disorder (HSDD)** in postmenopausal women, not as a standard treatment for vaginal dryness.
- It is not indicated as an initial management strategy for **vulvovaginal atrophy** in this clinical context.
Question 135: A 27-year-old woman presents requesting contraception. She mentions that she sometimes forgets to take daily medication. She has no significant medical history and takes no regular medications. Her BMI is 32 kg/m² and blood pressure is 118/76 mmHg. She is in a stable relationship and would like to have children in approximately 3 years. Which contraceptive method would be most appropriate to recommend?
A. Combined oral contraceptive pill
B. Progesterone-only pill
C. Etonogestrel subdermal implant (Correct Answer)
D. Depot medroxyprogesterone acetate injection
E. Levonorgestrel intrauterine system
Explanation: ***Etonogestrel subdermal implant***
- The implant is a **Long-Acting Reversible Contraceptive (LARC)**, effective for up to **3 years**, which perfectly aligns with the patient's stated desire to conceive in approximately 3 years.
- It eliminates the issue of **medication adherence** (forgetting daily pills) and offers a **rapid return to fertility** immediately upon removal.
*Combined oral contraceptive pill*
- This method requires **daily adherence**, which is unsuitable for a patient who mentions she **sometimes forgets daily medication**, increasing the risk of **user failure**.
- Her **BMI of 32 kg/m²** (obesity) is a relative contraindication for combined hormonal contraceptives due to a slightly increased risk of **venous thromboembolism (VTE)**.
*Progesterone-only pill*
- Similar to the combined oral contraceptive, the progesterone-only pill demands **strict daily timing** for effectiveness, making it a poor choice for someone with a history of **poor medication adherence**.
- Missing the tablet even by a few hours can compromise its efficacy, necessitating backup contraception or abstinence.
*Depot medroxyprogesterone acetate injection*
- While highly effective, this method requires injections every **12-13 weeks**, still necessitating regular clinic visits. It is also associated with **weight gain**, which may be a concern for a patient with a BMI of 32.
- It commonly causes a **delayed return to fertility**, potentially up to 12 months, which may conflict with her plan to have children in approximately 3 years.
*Levonorgestrel intrauterine system*
- This is an **effective LARC** but typically provides contraception for **5 years or more**, which is longer than her stated desire to conceive in approximately 3 years.
- It is an **invasive procedure** requiring insertion by a trained clinician and is often preferred for managing heavy menstrual bleeding, which is not a stated concern here.
Question 136: A 34-year-old woman attends for contraceptive counselling. She smokes 15 cigarettes per day and has a blood pressure of 158/98 mmHg on two separate occasions. Her BMI is 28 kg/m². She has no other medical history. Blood tests including renal function and lipid profile are normal. What is the most appropriate contraceptive method for this patient?
A. Combined oral contraceptive pill
B. Copper intrauterine device
C. Vaginal contraceptive ring
D. Progesterone-only pill (Correct Answer)
E. Combined transdermal patch
Explanation: ***Progesterone-only pill***
- The patient's **hypertension** (158/98 mmHg) and **smoking** are significant cardiovascular risk factors, making estrogen-containing contraceptives unsafe. The **progesterone-only pill (POP)** does not increase **thromboembolic** or **vascular risk** and is a **UKMEC 1** or **2** choice for her.
- It is the most appropriate hormonal oral contraceptive option for patients with contraindications to estrogen, such as **uncontrolled hypertension** and being a **smoker** over 35 or with other risk factors.
*Combined oral contraceptive pill*
- The **estrogen component** of combined oral contraceptives significantly increases the risk of **stroke** and **myocardial infarction** in patients with **uncontrolled hypertension** and smoking.
- This method is classified as **UKMEC 4** (unacceptable risk) for patients with blood pressure consistently above 140/90 mmHg, especially with other risk factors like smoking.
*Copper intrauterine device*
- While the **copper IUD** is a highly effective and medically safe **long-acting reversible contraceptive (LARC)** (UKMEC 1), the question asks for the most appropriate *contraceptive method* in general counselling.
- The progesterone-only pill is often considered a standard first-line oral alternative when combined hormonal methods are contraindicated, addressing the patient's immediate need for a safe oral option.
*Vaginal contraceptive ring*
- The vaginal ring, like other combined hormonal methods, delivers **systemic estrogen**, making it subject to the same contraindications as the combined oral pill due to the patient's **hypertension** and smoking.
- Its use is classified as **UKMEC 4** for individuals with blood pressure above **160/100 mmHg** or those with multiple vascular risk factors.
*Combined transdermal patch*
- The **combined transdermal patch** contains **estrogen** and carries similar cardiovascular risks to other combined hormonal contraceptives, including an increased risk of **venous thromboembolism** and arterial disease in hypertensive patients.
- The **transdermal route of administration** does not mitigate the contraindications posed by the patient's **hypertension** and **smoking status**.
Question 137: A 43-year-old woman attends for contraceptive advice. She is currently using condoms. She smokes 25 cigarettes per day and has a BMI of 33 kg/m². Her blood pressure is 142/90 mmHg on two separate occasions. She has regular menstrual cycles and wishes to continue menstruating. She has no other medical history. After counseling about smoking cessation and lifestyle modification, which contraceptive method would be most appropriate while addressing her cardiovascular risk profile?
A. Combined oral contraceptive pill
B. Progesterone-only pill (desogestrel) (Correct Answer)
C. Depot medroxyprogesterone acetate
D. Etonogestrel subdermal implant
E. Copper intrauterine device
Explanation: ***Progesterone-only pill (desogestrel)***- This method is safe (typically **UKMEC 1 or 2**) for women with multiple cardiovascular risk factors like **smoking**, **obesity**, and **hypertension**, as it does not contain estrogen.- It provides a suitable balance for a patient who **wishes to continue menstruating**, as it often allows for more predictable cycles compared to long-acting reversible contraceptives (LARCs) while avoiding the risks of combined pills.*Combined oral contraceptive pill*- This is strictly contraindicated (**UKMEC 4**) in this patient because she is over 35 years old and **smokes more than 15 cigarettes per day**.- The estrogen component significantly increases the risk of **myocardial infarction**, **stroke**, and **venous thromboembolism** in patients with pre-existing hypertension and cardiovascular risk factors.*Depot medroxyprogesterone acetate*- The injectable contraceptive is generally avoided (**UKMEC 3**) in patients with multiple cardiovascular risk factors due to potential adverse effects on **lipid profiles** and **weight gain**.- It is also associated with a high incidence of **amenorrhea** or persistent irregular spotting, which may not align with her preference to maintain a regular cycle.*Etonogestrel subdermal implant*- While safe from a cardiovascular standpoint, the implant frequently causes **amenorrhea** or highly irregular bleeding, which contradicts the patient's wish to continue menstruating.- It is a highly effective **LARC**, but user preference regarding menstrual patterns is a key factor in selecting the most "appropriate" method in this clinical scenario.*Copper intrauterine device*- Although the copper IUD is the safest option cardiovascularly (**UKMEC 1**), it is known to **increase menstrual blood loss** and cause heavier periods.- While it allows for natural menstruation, the potential for **menorrhagia** (heavy bleeding) often makes it less desirable for patients simply wishing to maintain their normal cycle without exacerbation.
Question 138: A 57-year-old woman with type 2 diabetes mellitus presents requesting HRT for moderate vasomotor symptoms that are affecting her sleep. Her last menstrual period was 3 years ago. Her HbA1c is 58 mmol/mol (7.5%), BMI is 29 kg/m², and blood pressure is 136/84 mmHg. She has background diabetic retinopathy but no other diabetic complications. She takes metformin and gliclazide. What factor would represent the greatest relative contraindication to HRT in this patient?
A. Type 2 diabetes mellitus
B. Her age of 57 years
C. Blood pressure of 136/84 mmHg (Correct Answer)
D. BMI of 29 kg/m²
E. Current glycaemic control
Explanation: ***Blood pressure of 136/84 mmHg*** - While not an absolute contraindication, **blood pressure** must be carefully managed as oral estrogen can potentially increase blood pressure and the risk of **stroke**. - In patients with **Diabetes Mellitus**, blood pressure targets are often stricter, and this reading approaches the threshold where **hypertension** needs to be stabilized before starting treatment. *Type 2 diabetes mellitus* - Diabetes is classified as **UKMEC 2**, meaning the benefits of HRT generally outweigh the risks, and it is not a direct contraindication. - HRT can actually have positive effects on **glucose metabolism** and insulin sensitivity in many menopausal women. *Her age of 57 years* - Commencing HRT at age 57 is generally safe, as it falls within the **"window of opportunity"** (under age 60 or within 10 years of menopause onset). - At this age, the **cardiovascular benefit-to-risk ratio** remains favorable for treating symptomatic women. *BMI of 29 kg/m²* - A BMI in the overweight range is a **UKMEC 2** factor; while it increases baseline **venous thromboembolism (VTE)** risk, it does not preclude HRT use. - For women with higher BMIs, **transdermal HRT** is preferred as it avoids the increased VTE risk associated with oral preparations. *Current glycaemic control* - An HbA1c of 58 mmol/mol (7.5%) indicates suboptimal control, but it is not a **relative contraindication** to hormone therapy. - HRT does not typically worsen **glycaemic control** and is safe to use alongside metformin and sulfonylureas like **gliclazide**.
Question 139: A 33-year-old woman with a 6-month history of migraine with aura has been using combined oral contraceptive pills for 4 years. She presents for a routine contraceptive review. Her migraines have increased in frequency from once every 3 months to 2-3 times per month over the past 6 months. She has no other medical history and her blood pressure is 122/78 mmHg. What is the most appropriate management of her contraception?
A. Continue combined oral contraceptive as migraines are well-controlled
B. Switch to progesterone-only pill (Correct Answer)
C. Reduce the estrogen dose in her combined oral contraceptive
D. Switch to tricycling regimen to reduce pill-free intervals
E. Continue current pill but add prophylactic migraine treatment
Explanation: ***Switch to progesterone-only pill***- Combined hormonal contraception (CHC) is a **UKMEC 4** (unacceptable health risk) contraindication in patients with **migraine with aura** due to an increased risk of **ischemic stroke**.- Progesterone-only methods, such as the **progesterone-only pill (POP)**, do not contain estrogen and are considered safe (**UKMEC 2**) for women who experience migraines with aura.*Continue combined oral contraceptive as migraines are well-controlled*- Regardless of frequency or control, the presence of **aura** makes estrogen-containing pills strictly contraindicated because of the **cardiovascular risk profile**.- These migraines are actually increasing in frequency (2-3 times per month), which further contraindicates the use of high-risk hormonal medications.*Reduce the estrogen dose in her combined oral contraceptive*- Lowering the **estradiol dose** does not eliminate the contraindication; any amount of estrogen in the context of aura significantly elevates **stroke risk**.- **UKMEC 4** guidelines apply to all forms of combined contraception, including low-dose pills, patches, and vaginal rings.*Switch to tricycling regimen to reduce pill-free intervals*- **Tricycling** (taking three packs back-to-back) is used to manage **estrogen-withdrawal migraines** (migraine without aura), but it is unsafe here.- Because this patient experiences **aura**, the primary concern is the safe use of estrogen itself, not just the fluctuations during the **pill-free interval**.*Continue current pill but add prophylactic migraine treatment*- Prophylactic treatment for migraines does not mitigate the **thromboembolic and stroke risks** associated with using CHC in patients with aura.- The priority in clinical management is to **discontinue the estrogen component** immediately to ensure the patient's long-term safety.
Question 140: A 56-year-old woman who has been on continuous combined HRT for 3 years presents for review. She remains asymptomatic with good control of vasomotor symptoms. She asks about when she should stop HRT. She has no history of premature ovarian insufficiency, cardiovascular disease, or osteoporosis risk factors. What is the most appropriate advice regarding continuation of HRT?
A. HRT should be stopped immediately as she has been on it for more than 2 years
B. HRT can be continued if benefits outweigh risks, with annual review (Correct Answer)
C. HRT should be stopped at age 60 regardless of symptoms
D. HRT should be continued until age 65 to protect against osteoporosis
E. HRT should be gradually reduced and stopped within 6 months
Explanation: ***HRT can be continued if benefits outweigh risks, with annual review***- Current guidelines emphasize an **individualized assessment** for HRT duration, with **no arbitrary time limit**.- The decision to continue should be based on ongoing **symptom control**, quality of life, and a personal risk-benefit analysis during an **annual review**.*HRT should be stopped immediately as she has been on it for more than 2 years*- There is no medical requirement or guideline to stop HRT after a **fixed two-year period**; symptom duration varies greatly.- Immediate cessation is not indicated unless there's a **new contraindication** or significant adverse effects.*HRT should be stopped at age 60 regardless of symptoms*- While risks can increase with age, **age 60 is not an absolute cutoff** for HRT, especially if symptoms are well-controlled.- Stopping HRT regardless of symptoms ignores the patient's **symptomatic relief** and potential recurrence of vasomotor symptoms.*HRT should be continued until age 65 to protect against osteoporosis*- Although HRT is effective for **osteoporosis prevention**, it is generally not recommended as a first-line long-term treatment solely for this purpose in women without high fracture risk.- The duration of HRT should primarily be driven by **symptomatic need** and quality of life, not a specific target age like 65 for bone protection.*HRT should be gradually reduced and stopped within 6 months*- While some women may choose to **taper the dose** to assess symptom recurrence, there is no mandatory requirement to stop within a 6-month timeframe.- Forcing a reduction and stop in an **asymptomatic patient** benefiting from HRT contradicts the principle of individualized, patient-centered care.
